Phage display

Phage display has since its inception in the late 1980s, become a versatile tool for discovery of new therapeutic monoclonal antibodies. The tool is also increasingly used for discovery of other types of therapeutic molecules.

Innovations

Nextera’s CSO  Geir Åge Løset is co-author of a recent publication describing improvements for effective screening and recovery of soluble T-cell receptors. Read more.

New products

Taggerphage brings additional functionality to existing phage display, and opens for easier and more straight forward detection and purification of selected binding partners. It will also simplify detection of a broader range of molecules.

Nextera is a drug discovery company based on a proprietary phage display technology and with a focus on new therapies for autoimmune diseases. Most autoimmune diseases share the common feature of having unknown antigens and complex disease pathogenesis. Consequently, current therapies are mainly symptom modifying. Through our phage display technology, we aim to identify these unknown antigens, and exploit this knowledge to develop new and highly focused targeted pharmaceuticals. The effect will be improved drug efficacy devoid of or highly reduced in adverse and side effects seen with current therapies, which rely on a much broader mode of action. Our vision is to be one of Europe´s five leading sources of new drug targets and drug candidates for autoimmune diseases within 2016.

Nextera is based on technology from the internationally renowned group of Professor Inger Sandlie at the University of Oslo. Sandlie’s group is one of the pioneers in the field of antibody engineering with articles in highly rated journals such as Nature, Nature reviews in drug discovery and PNAS.